Takeda's Pipeline Looks Encouraging, But Generic Erosion Is A Near-Term Concern

Takeda Pharmaceutical remains a hold, with shares near 52-week highs and uncertainty about a major successor to Entyvio. TAK's Q1 showed 10% revenue growth but bottom-line weakness from higher taxes and lower operating cash flow due to mounting receivables. Orzeyful's FDA approval is promising, but its commercial impact is likely limited compared to Entyvio; pipeline drugs like zasocitinib offer longer-term potential, but how much is as yet uncertain. With Entyvio's patent expiry looming in 2030 and generic erosion evident in Vyvanse, TAK's growth outlook is speculative at current valuations.

We last took a look at Takeda Pharmaceutical ( TAK ) in January, and I downgraded the stock from a buy to a hold both on the basis that they had approached a 52-week